Evidence-based treatment guidelines, including the Canadian Thoracic Society’s 2019 guideline, clearly define the place of triple inhaled therapy in the management of chronic obstructive pulmonary disease (COPD). However, pharmacists may have inadequate knowledge about some aspects of COPD management, and may harbour misconceptions, including about the role of triple therapy versus dual inhaled therapy in COPD, treatment selection for COPD according to the patient, differences between various COPD inhaler devices, and the safety profiles of inhaled corticosteroids (ICS) used in COPD. This educational program discusses these aspects of triple therapy in COPD and addresses prevailing myths/misconceptions.
Setting the facts straight around triple therapy in COPD – CCCEP
CAN-eng
$0
free
CCCEP
1.5 hours
Respirology
1.5 Credits
Course Description
Course Details
Expiry Date: 2021-04-21
Professions: Pharmacy
Faculty
- Charles Chan, MD, FRCPC, FCCP, FACP
- Olivia Ng, BScPhm, RPh, PharmD
- Simon Lessard, Pharm.D., MBA, CRE, CTE
Accreditation
This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 1.5 CEU(s).
CCCEP File Number: 1066-2020-3008-I-P
Learning Objective(s)
On completion of this program, participants should be able to:
- Describe the place of triple inhaled therapy versus dual bronchodilators in the management of chronic obstructive pulmonary disease (COPD);
- Discuss the selection of inhaled drug therapy for COPD according to the patient symptoms and risks of exacerbations
- Describe the differences for various COPD inhaler types in regards to ease of use, minimum inspiratory flow requirements and peak inspiratory flow requirements
- Discuss the safety profile of inhaled corticosteroids in triple combination regimens for COPD